- Home
- CHCI vs CMRX Comparison
CHCI vs CMRX Comparison
Compare CHCI & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCI
- CMRX
- Stock Information
- Founded
- CHCI 1985
- CMRX 2000
- Country
- CHCI United States
- CMRX United States
- Employees
- CHCI N/A
- CMRX N/A
- Industry
- CHCI Building operators
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CHCI Real Estate
- CMRX Health Care
- Exchange
- CHCI Nasdaq
- CMRX Nasdaq
- Market Cap
- CHCI 82.0M
- CMRX 77.1M
- IPO Year
- CHCI 2004
- CMRX 2013
- Fundamental
- Price
- CHCI $7.99
- CMRX $3.82
- Analyst Decision
- CHCI
- CMRX Strong Buy
- Analyst Count
- CHCI 0
- CMRX 2
- Target Price
- CHCI N/A
- CMRX $8.50
- AVG Volume (30 Days)
- CHCI 14.1K
- CMRX 1.6M
- Earning Date
- CHCI 11-07-2024
- CMRX 02-27-2025
- Dividend Yield
- CHCI N/A
- CMRX N/A
- EPS Growth
- CHCI N/A
- CMRX N/A
- EPS
- CHCI 0.59
- CMRX N/A
- Revenue
- CHCI $45,402,000.00
- CMRX $159,000.00
- Revenue This Year
- CHCI N/A
- CMRX N/A
- Revenue Next Year
- CHCI N/A
- CMRX $1,690.28
- P/E Ratio
- CHCI $14.28
- CMRX N/A
- Revenue Growth
- CHCI 5.57
- CMRX N/A
- 52 Week Low
- CHCI $4.55
- CMRX $0.75
- 52 Week High
- CHCI $14.48
- CMRX $4.07
- Technical
- Relative Strength Index (RSI)
- CHCI 55.91
- CMRX 70.87
- Support Level
- CHCI $7.70
- CMRX $3.43
- Resistance Level
- CHCI $8.46
- CMRX $4.07
- Average True Range (ATR)
- CHCI 0.54
- CMRX 0.31
- MACD
- CHCI 0.09
- CMRX -0.04
- Stochastic Oscillator
- CHCI 72.00
- CMRX 74.74
About CHCI Comstock Holding Companies Inc.
Comstock Holding Co Inc is a developer and manager of mixed-use and transit-oriented properties with operations that are majorly focused on the Washington, D.C. metropolitan area. It provides a range of services such as asset management, property management, development and construction management, and other real estate-related services to its asset-owning clients, composed predominantly of institutional real estate investors, high net worth family offices, financial institutions, and governmental bodies seeking to enhance their surrounding communities by developing real estate through public-private partnerships.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.